Sydney startup Lumonus raises $25M for AI in oncology

🧬 Clairity Raises $43M Series B to Advance #AI-Powered Precision Health Clairity, Inc., a Boston-based AI-driven precision health company, has raised $43M in Series B funding. The round was led by ACE Global Equity and Santé Ventures, with continued participation from the The Breast Cancer Research Foundation (BCRF) and several new investors. This new capital will support the commercialization of Clairity Breast—the company’s FDA-cleared platform that predicts a woman’s five-year breast cancer risk directly from a routine mammogram. Clairity will also accelerate development of Clairity Breast 3D and Clairity Heart, its next product focused on predicting cardiovascular risk from the same standard imaging exam. Led by CEO & President Jeffrey R. Luber, Clairity is transforming medical imaging into a proactive predictive tool for early disease risk assessment. With FDA authorization secured and initial deployment underway across health systems, the company is expanding its AI pipeline to address additional major diseases. 🚀 A meaningful step forward in improving early detection and personalized care through AI. #Clairity #HealthTech #PrecisionHealth #AIinHealthcare #BreastCancerAwareness #CardiovascularHealth #MedicalImaging #AIDiagnostics #SantéVentures #ACEGlobalEquity #SeriesB #HealthcareInnovation #DigitalHealth #FDAcleared #BostonStartups

As #ESMO2025 closes, one message resonates: depth of science now meets depth of strategy. Even from afar, it’s clear this year’s conversation was about how data connect to daily practice. Companies like Johnson & Johnson, Roche, Bristol Myers Squibb, and AbbVie stood out for robust portfolios and clear clinical direction. HCPs were most energized by subcutaneous innovation, real-world integration, and long-term survival data that translate into action. For Medical Affairs, the task ahead is orchestration — aligning science, access, and patient experience into a single narrative that drives adoption. What stood out most for you from #ESMO2025 — the data, the delivery, or the dialogue? #MedicalAffairs #Oncology #EvidenceToAction #LaunchExcellence #PharmaStrategy #ClinicalInsights

DelveInsight estimates that the Real-World Evidence (RWE) Solutions Market will grow at a CAGR of 8.07% through 2032.: Real-World Evidence (RWE) Solutions Market According to the latest data provided by the Global Cancer Observatory (2024), in 2022, the estimated number of new cancer cases globally was 20 million, with projections indicating a rise to 32.6 million cases by … Continue reading → #Europe #HealthMedicine #PharmaceuticalsBiotech #UK #US

As everyone settles back in at home after #ESMO2025, it is clear that oncology is shifting from efficacy first to experience always. We should expect to hear steady chatter around how data translates into comfort, longevity, and access for patients ... and what this means for the pharma companies bringing solutions forward and the HCPs delivering care. Discussions around subcutaneous formulations, real-world durability, and expanded telehealth access all signaled that innovation now extends beyond the molecule. As we look towards 2026, expect integration to define progress: cross-modality combinations, earlier-stage indications, and AI-driven evidence shaping faster decision-making. Medical Affairs teams must embrace that their role is evolving from communicating data to orchestrating understanding. If we do so, we will be aligning science, access, and education so new therapies reach patients sooner. I'd love to hear what #ESMO2025 theme you think will drive oncology’s next chapter in? #MedicalAffairs #Oncology #EvidenceToAction #PatientCentricity #ClinicalInsights #ReimagineHealth

Day 5 of #ESMO2025 confirmed a pattern: that it's not only about how the mechanism works, but how it works at scale, in practice, and in context. The role of medical affairs seems clear: bridge mechanism to patient experience, build the operational story, and align internal/external stakeholders around real-world implications. Tomorrow and Thursday, I plan to summarize ESMO 2025 around 4 areas: 1) Which pharma companies stood out for their science and storytelling 2) What truly energized HCPs 3) What all this means for patients 4) How Medical Affairs, can help lead what comes next #ESMO2025 #MedicalAffairs #Oncology #LaunchExcellence #EvidenceToAction #PharmaStrategy #ClinicalInsights

Inspiring dialogue and incredible energy at the 15th Annual AVBCC Summit! This year’s discussions captured the continued evolution of value-based oncology. While “value” may take on different definitions, the emphasis was clear — multi-stakeholder collaboration, cost transparency, AI enablement, and accountability are essential drivers of sustainable progress. What resonated most was the collective recognition that information, integrity, transparency, and innovation must come together to build models that truly create value for all stakeholders — patients, providers, payers, and pharma alike. One truth remains constant: value-based care takes time, requires significant investment, and depends on trusted partnerships to design and scale models that endure. With the rise and acceleration of AI, we now have a powerful catalyst to unlock new efficiencies, accelerate insights, and transform healthcare delivery — bridging the gap between vision and execution. Transforming cancer care demands alignment, accountability, and the courage to reimagine the status quo. I left this summit inspired and energized by the shared commitment to make value-based oncology not just an aspiration, but a tangible, shared reality. #AVBCC #ValueBasedCare #Oncology #HealthEquity #AlignedHealthcare #Collaboration #HealthcareTransformation #Leadership

A Global 200 life sciences leader partnered with Perficient to accelerate the launch of a fully automated cancer staining solution—without compromising precision or compliance. We integrated sample management software to automate the entire workflow, from sample processing to test results, across multiple hardware platforms. Our MedTech automation and software expertise help drive innovation in cancer diagnostics. See how we partner with life sciences leaders to bring breakthrough solutions to market faster. 👉 https://lnkd.in/giCBekRG #HealthcareTechnology #LifeScience #DigitalInnovation #MedicalTechnology #ClientSuccess

CE is more than just a requirement — it’s a tool for better patient care and smarter clinical decisions. 💙 Recent findings show that most oncology professionals see tangible improvements in outcomes after engaging in continuing education programs. Staying current with the latest research, therapies, and best practices can make a real difference in your daily practice and for the patients you treat. Invest in your learning, invest in your patients. 🩺 #OncologyEducation #CEImpact #CancerCare #OncologyProfessionals #LoneStarOncology #CollaborateAdvanceInnovate #MedicalLearning

A Global 200 life sciences leader partnered with Perficient to accelerate the launch of a fully automated cancer staining solution—without compromising precision or compliance.   We integrated sample management software to automate the entire workflow, from sample processing to test results, across multiple hardware platforms. Our MedTech automation and software expertise help drive innovation in cancer diagnostics. See how we partner with life sciences leaders to bring breakthrough solutions to market faster. 👉 https://lnkd.in/giCBekRG     #HealthcareTechnology #LifeScience #DigitalInnovation #MedicalTechnology #ClientSuccess

myTomorrows has raised $29M in a growth equity round led by Avego to support the global expansion of its AI-powered platform for pre-approval patient access to therapies. CEO Michel van Harten emphasized the role of this investment in accelerating access to innovative treatments worldwide, with Avego's expertise strengthening myTomorrows’ partnerships and platform integration. Syed Hamza Sohai | HIT Consultant Media https://lnkd.in/ehvtB-jN #HealthTech